You are using an older browser version. Please use a supported version for the best MSN experience.

This biotech growth stock is hammering the AstraZeneca share price. Here’s what you need to know

The Motley Fool logo The Motley Fool 9/14/2020 Alan Oscroft
a clock hanging from the ceiling: Screen of various price trends, possibly in FTSE 100 © Provided by The Motley Fool Screen of various price trends, possibly in FTSE 100

Pharmaceuticals stocks like AstraZeneca (LSE: AZN) are doing well in 2020, for obvious reasons. The AstraZeneca share price is up 9.5% this year, while the FTSE 100 is down 20%. Some biotechnology stocks are doing even better, and  Silence Therapeutics (LSE: SLN) is one of them, with a share price gain of 35%.

Silence has a proprietary technology platform for drug development based on RNA interference. That provides researchers with the ability to develop treatments to selectively inhibit gene expression. I don’t have the expertise to know what’s likely to come from it. But anything that provides the ability to selectively target specific genes responsible for diseases just has to be a good thing.

The company isn’t profitable yet, and that does make it very hard to place a valuation on its shares. I’d expect volatility too, and a comparison with the AstraZeneca share price is telling. Over the past five years, the two have had a pretty similar overall result. Silence Therapeutics is up 77%, while AstraZeneca has the edge with a 92% gain. But that’s where the similarity ends.

A recent ten-bagger

AstraZeneca shares have been climbing steadily, while the Silence Therapeutics chart shows a history of boom and bust. Or perhaps bust and boom, as the price had been in a slump until the middle of 2019. But since then, Silence shares have soared more than tenfold in value, easily beating the AstraZeneca share price in the short term.

For the first half of the year, Silence Therapeutics recorded an £11m loss after tax. But it reported cash equivalents and term deposits of £50.3m at 30 June, which looks healthy. That’s an increase, and it’s driven by the firm’s collaboration with AstraZeneca. The firm received a cash payment of $60m and an equity investment of $20m, and stands to reap “up to $400 million in potential milestones for each target plus tiered royalties“.

AstraZeneca share price picking up

Video: Investors Were Interested in Stocks This Week -- Even as S&P 500 Was Pressured (TheStreet)


Speaking of AstraZeneca, the pharmaceuticals giant had just paused its late-stage Covid-19 study after a patient taking part reported a side effect. But the trial has already been resumed. The AstraZeneca share price hasn’t done much yet in response, but hopefully any renewed Covid-19 pessimism will have subsided a little.

Meanwhile, the AstraZeneca resurgence under boss Pascal Soriot continues. The company’s shares had been in the dumps due to the loss of patents and a drying up development pipeline. Big investment in research is reversing that situation, though it was always going to be a long-term project.

Not too late to buy

But with the AstraZeneca share price’s impressive performance of the past five years, have investors missed the boat? I’d say a big no to that.

Profits from the firm’s refocused research and development are really only just starting to come through. Forecasts suggest a price-to-earnings multiple for 2021 of a little over 20, and I reckon a few years of earnings growth could soon see that tumble. And that should feed through to higher dividend yields too, currently at around 2.6%.

A Top Share with Enormous Growth Potential

Savvy investors like you won’t want to miss out on this timely opportunity…

Here’s your chance to discover exactly what has got our Motley Fool UK analyst all fired up about this ‘pure-play’ online business (yes, despite the pandemic!).

Not only does this company enjoy a dominant market-leading position…

But its capital-light, highly scalable business model has previously helped it deliver consistently high sales, astounding near-70% margins, and rising shareholder returns … in fact, in 2019 it returned a whopping £150m+ to shareholders in dividends and buybacks!

And here’s the really exciting part…

While COVID-19 may have thrown the company a curveball, management have acted swiftly to ensure this business is as well placed as it can be to ride out the current period of uncertainty… in fact, our analyst believes it should come roaring back to life, just as soon as normal economic activity resumes.

That’s why we think now could be the perfect time for you to start building your own stake in this exceptional business – especially given the shares look to be trading on a fairly undemanding valuation for the year to March 2021.

Click here to claim your copy of this special report now — and we’ll tell you the name of this Top Growth Share… free of charge!

More reading

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

The post This biotech growth stock is hammering the AstraZeneca share price. Here’s what you need to know appeared first on The Motley Fool UK.


More from The Motley Fool

The Motley Fool
The Motley Fool
image beaconimage beaconimage beacon